Vaccine effectiveness against infection with the delta (b.1.617.2) variant, norway, april to august 2021

53Citations
Citations of this article
72Readers
Mendeley users who have this article in their library.

Abstract

Some variants of SARS-CoV-2 are associated with increased transmissibility, increased disease severity or decreased vaccine effectiveness (VE). In this population-based cohort study (n = 4,204,859), the Delta variant was identified in 5,430 (0.13%) individuals, of whom 84 were admitted to hospital. VE against laboratory confirmed infection with the Delta variant was 22.4% among partly vaccinated (95% confidence interval (CI): 17.0-27.4) and 64.6% (95% CI: 60.6-68.2) among fully vaccinated individuals, compared with 54.5% (95% CI: 50.4-58.3) and 84.4% (95%CI: 81.8-86.5) against the Alpha variant.

Cite

CITATION STYLE

APA

Seppälä, E., Veneti, L., Starrfelt, J., Danielsen, A. S., Bragstad, K., Hungnes, O., … Meijerink, H. (2021). Vaccine effectiveness against infection with the delta (b.1.617.2) variant, norway, april to august 2021. Eurosurveillance, 26(35). https://doi.org/10.2807/1560-7917.ES.2021.26.35.2100793

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free